alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Amplification'],"[{'ncitCode': 'C179323', 'drugName': 'Lunresertib'}, {'ncitCode': 'C174206', 'drugName': 'Camonsertib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['38410486'],"[{'link': 'https://aacrjournals.org/mct/article/22/12_Supplement/B057/730329/Abstract-B057-Preclinical-development-of-PKMYT1)(Abstract', 'abstract': 'Gallo, D. et al., Abstract# B057, AACR 2023.'}, {'link': 'https://www.reparerx.com/wp-content/uploads/2023/10/ANE_B156_MYTHIC-clinical_poster.pdf', 'abstract': '# B156, AACR-NCI-EORTC 2023.'}, {'link': 'https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852', 'abstract': 'Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023.'}]","Lunresertib is an orally available, small molecule PKMYT1 inhibitor and camonsertib is an orally available, small molecule ATR inhibitor. There are promising clinical data of response to lunresertib plus camonsertib in patients with CCNE1-amplified gynecologic cancers. In the Phase I MYTHIC (NCT04855656) trial of lunresertib plus camonsertib in patients with advanced tumors harboring CCNE1 amplifications, FBXW7 deleterious mutations or PPP2R1A deleterious mutations, the lunresertib plus camonsertib cohort (n=59 [n=17, endometrial; n=13, colorectal; n=11, ovarian; n=3, breast; n=3, lung; n=12, other]) demonstrated an overall response rate of 23.6% in all evaluable patients across tumor types, with a 33.3% response rate in patients with CCNE1-amplified tumors and a 38.5% response rate in patients with gynecologic cancers across all dosages (Abstract: Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023. https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852). Preclinical studies with ovarian and endometrial cancer cell lines and xenograft models expressing CCNE1 amplification demonstrate sensitivity to lunresertib plus camonsertib as measured by tumor regression and decreased cellular viability (PMID: 38410486) (Abstract: Gallo, D. et al., Abstract# B057, AACR 2023. https://aacrjournals.org/mct/article/22/12_Supplement/B057/730329/Abstract-B057-Preclinical-development-of-PKMYT1)(Abstract: Yap, T. et al., Abstract# B156, AACR-NCI-EORTC 2023. https://www.reparerx.com/wp-content/uploads/2023/10/ANE_B156_MYTHIC-clinical_poster.pdf)."
['Amplification'],"[{'ncitCode': 'C179323', 'drugName': 'Lunresertib'}, {'ncitCode': 'C174206', 'drugName': 'Camonsertib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 884, 'code': '', 'color': 'PeachPuff', 'name': '', 'mainType': {'id': None, 'name': 'Endometrial Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Uterus', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['38410486'],"[{'link': 'https://aacrjournals.org/mct/article/22/12_Supplement/B057/730329/Abstract-B057-Preclinical-development-of-PKMYT1)(Abstract', 'abstract': 'Gallo, D. et al., Abstract# B057, AACR 2023.'}, {'link': 'https://www.reparerx.com/wp-content/uploads/2023/10/ANE_B156_MYTHIC-clinical_poster.pdf', 'abstract': '# B156, AACR-NCI-EORTC 2023.'}, {'link': 'https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852', 'abstract': 'Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023.'}]","Lunresertib is an orally available, small molecule PKMYT1 inhibitor and camonsertib is an orally available, small molecule ATR inhibitor. There are promising clinical data of response to lunresertib plus camonsertib in patients with CCNE1-amplified gynecologic cancers. In the Phase I MYTHIC (NCT04855656) trial of lunresertib plus camonsertib in patients with advanced tumors harboring CCNE1 amplifications, FBXW7 deleterious mutations or PPP2R1A deleterious mutations, the lunresertib plus camonsertib cohort (n=59 [n=17, endometrial; n=13, colorectal; n=11, ovarian; n=3, breast; n=3, lung; n=12, other]) demonstrated an overall response rate of 23.6% in all evaluable patients across tumor types, with a 33.3% response rate in patients with CCNE1-amplified tumors and a 38.5% response rate in patients with gynecologic cancers across all dosages (Abstract: Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023. https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852). Preclinical studies with ovarian and endometrial cancer cell lines and xenograft models expressing CCNE1 amplification demonstrate sensitivity to lunresertib plus camonsertib as measured by tumor regression and decreased cellular viability (PMID: 38410486) (Abstract: Gallo, D. et al., Abstract# B057, AACR 2023. https://aacrjournals.org/mct/article/22/12_Supplement/B057/730329/Abstract-B057-Preclinical-development-of-PKMYT1)(Abstract: Yap, T. et al., Abstract# B156, AACR-NCI-EORTC 2023. https://www.reparerx.com/wp-content/uploads/2023/10/ANE_B156_MYTHIC-clinical_poster.pdf)."
['Amplification'],"[{'ncitCode': 'C179323', 'drugName': 'Lunresertib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],['35444283'],"[{'link': 'https://aacrjournals.org/mct/article/22/12_Supplement/PR008/730843/Abstract-PR008-MYTHIC-First-in-human-FIH-biomarker', 'abstract': 'Yap et al. Abstract# PR008, AACR 2023.'}]","Lunresertib is an inhibitor of the cyclin E1 inhibitory kinase PKMYT1. Inhibition of cyclin E1 function is an attractive therapeutic avenue in tumors overexpressing cyclin E1. Preclinical studies of lunresertib in cell line-derived and patient-derived xenograft models of cyclin E1-amplified tumor cells demonstrated that PKMYT1 inhibition leads to tumor regression in various tumor models compared to cells with normal cyclin E1 expression (PMID: 35444283). In the Phase I MYTHIC (NCT04855656) trial of lunresertib alone or in combination with the ATR inhibitor camonsertib in 108 patients with solid tumors harboring CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A (uterine [31.5%], colorectal [20.4%], ovarian [16.7%], others [31.5%]), a patient with CCNE1-amplified bile duct cancer and two patients with CCNE1-amplified ovarian cancer were treated with lunresertib and camonsertib, resulting in a confirmed clinical response and CA-125 responses, respectively (Abstract: Yap et al. Abstract# PR008, AACR 2023. https://aacrjournals.org/mct/article/22/12_Supplement/PR008/730843/Abstract-PR008-MYTHIC-First-in-human-FIH-biomarker)."
['Amplification'],"[{'ncitCode': 'C179323', 'drugName': 'Lunresertib'}, {'ncitCode': 'C174206', 'drugName': 'Camonsertib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],['38410486'],"[{'link': 'https://aacrjournals.org/mct/article/22/12_Supplement/B057/730329/Abstract-B057-Preclinical-development-of-PKMYT1)(Abstract', 'abstract': 'Gallo, D. et al., Abstract# B057, AACR 2023.'}, {'link': 'https://www.reparerx.com/wp-content/uploads/2023/10/ANE_B156_MYTHIC-clinical_poster.pdf', 'abstract': '# B156, AACR-NCI-EORTC 2023.'}, {'link': 'https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852', 'abstract': 'Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023.'}]","Lunresertib is an orally available, small molecule PKMYT1 inhibitor and camonsertib is an orally available, small molecule ATR inhibitor. There are promising laboratory and anecdotal clinical data to support use of lunresertib plus camonsertib in patients with CCNE1-amplified solid tumors. In the Phase I MYTHIC (NCT04855656) trial of lunresertib plus camonsertib in patients with advanced tumors harboring CCNE1 amplifications, FBXW7 deleterious mutations or PPP2R1A deleterious mutations, the lunresertib plus camonsertib cohort (n=59 [n=17, endometrial; n=13, colorectal; n=11, ovarian; n=3, breast; n=3, lung; n=12, other]) demonstrated an overall response rate of 23.6% in all evaluable patients across tumor types (n=55), with a 33.3% response rate in patients with CCNE1-amplified tumors (n=18) and a confirmed partial response in a patient with CCNE1-amplified bile duct cancer (Abstract: Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023. https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852). Preclinical studies with ovarian and endometrial cancer cell lines and xenograft models expressing CCNE1 amplification demonstrate sensitivity to lunresertib plus camonsertib as measured by tumor regression and decreased cellular viability (PMID: 38410486) (Abstract: Gallo, D. et al., Abstract# B057, AACR 2023. https://aacrjournals.org/mct/article/22/12_Supplement/B057/730329/Abstract-B057-Preclinical-development-of-PKMYT1)(Abstract: Yap, T. et al., Abstract# B156, AACR-NCI-EORTC 2023. https://www.reparerx.com/wp-content/uploads/2023/10/ANE_B156_MYTHIC-clinical_poster.pdf)."
['Amplification'],"[{'ncitCode': 'C188045', 'drugName': 'BLU-222'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],[],"[{'link': 'https://aacrjournals.org/cancerres/article/82/12_Supplement/2306/703534', 'abstract': 'Brown, et al. Abstract# 2306, AACR 2022.'}]","BLU-222 is an inhibitor of CDK2, the cyclin E1 binding partner. Inhibition of cyclin E1 function is an attractive therapeutic avenue in tumors overexpressing cyclin E1. Preclinical studies of BLU-222 demonstrated in vitro and in vivo sensitivity of cyclin E1-amplified ovarian cancer cell lines to CDK2 inhibition, with tumor regression noted in xenograft tumor models when combined with carboplatin versus carboplatin alone (Abstract: Brown, et al. Abstract# 2306, AACR 2022. https://aacrjournals.org/cancerres/article/82/12_Supplement/2306/703534)."
